Abbott launches rapid point-of-care blood glucose test

By staff writers

June 17, 2019 -- Abbott has launched its Afinion hemoglobin A1c (HbA1c) Dx test for use in diagnosing diabetes and monitoring blood glucose in point-of-care settings. The company said the assay may be used to deliver results in three minutes, informing discussions between physicians and patients during office visits.

The rapid test was cleared by the U.S. Food and Drug Administration (FDA) in May 2018 for use with the company's Afinion AS100 analyzer to measure HbA1c, diagnose diabetes, and assess risk for developing the condition. It received clearance from the agency for use with the company's Afinion 2 multiassay analyzer in November 2018.

Abbott's Afinion HbA1c point-of-care assay for monitoring only was cleared by the FDA in 2005.

Study homes in on genetic risk for type 2 diabetes
An exome sequencing study of almost 46,000 people has pinpointed four genes with rare variants that put people at risk for type 2 diabetes, a large team...

Copyright © 2019

Last Updated np 6/17/2019 1:46:38 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.